Skip to content

Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test

Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00236171
Enrollment
14
Registered
2005-10-12
Start date
2004-09-30
Completion date
2010-06-30
Last updated
2010-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis Vulgaris

Keywords

topical therapy, Psoriasis Plaque Test

Brief summary

The purpose of this study is to evaluate the efficacy of the topical therapies Protopic and Advantan as well as their combination against placebo in a Psoriasis Plaque Test

Detailed description

daily psoriasis plaque tests for two weeks and optical coherence tomography (OCT) and 20-MHz-ultrasound on day 0 and day 11, 10 days post end of treatment and 20 days post end of treatment

Interventions

DRUGProtopic, Advantan
PROCEDUREcoherence tomography

Sponsors

Technische Universität Dresden
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients older than 18 Years * Negative urine pregnancy test * Written informed consent * Good compliance

Exclusion criteria

* Patients less than 18 years * Pregnant patients * Patients with renal insufficiency, liver diseases * Patients who received systemic antipsoriatic treatment or UV treatment less than 4 weeks prior to study * Patients who used topical antipsoriatics within two weeks prior to study * Immunosuppressed Patients

Design outcomes

Primary

MeasureTime frame
sum score of psoriasis plaque tests on day 11

Secondary

MeasureTime frame
20-MHz-ultrasound and OCT on day 11

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026